Prous Science
Prous Science was a Barcelona-based international publisher and information company focused on pharmacology, drug discovery, biomedical research, and health sciences.
Last updated August 24, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Prous Science was an international health-science publishing company established in 1965 and headquartered in Barcelona, Catalonia, Spain. Its activities centered on the creation and distribution of specialized scientific information, particularly in pharmacology, drug discovery, biomedical research, and related areas of pharmaceutical science. The company operated internationally, with offices or subsidiaries in Barcelona, Philadelphia, Buenos Aires, and Tokyo, giving it a presence across European, North American, Latin American, and Asian markets. The brand combined conventional scientific publishing with structured information services intended for researchers and professionals working in pharmaceutical discovery and biomedical development. Its subject areas included pharmacological literature, drug-related data, medicinal chemistry, and scientific methods relevant to identifying and evaluating therapeutic compounds. Prous Science also developed information products that used computational techniques to organize and analyze complex biomedical and chemical information. A significant part of the company's identity was its emphasis on data-driven scientific research. Its work incorporated data mining, statistical analysis, and chemoinformatics, alongside laboratory approaches such as combinatorial chemistry, molecular biology, and functional genomics. Prous described this combination as “druginformatics,” an approach intended to support the interpretation of drug and biomedical data through computational and experimental methods. The company expanded beyond publishing through the Prous Institute for Biomedical Research, established in 2000 as a biotechnology spin-off of Prous Science. The institute was founded by Dr. Josep Prous Jr. and pursued research based on computational analysis and laboratory science. This structure connected the publishing business with applied biomedical and drug-discovery research, although the two activities were presented as distinct parts of the broader Prous organization. In 2001, Prous Science launched the Prous Scientific Integrity data portal. The portal reflected the company's effort to provide specialized, organized scientific information rather than relying solely on conventional books and journals. After Thomson Reuters acquired Prous Science in 2007, Prous pharmacology and drug-discovery content was incorporated into Thomson Reuters services in 2008. Publicly available reference material does not establish a separate current operating structure for the original Prous Science company or provide a current standalone website, executive roster, or financial profile.
History
Prous Science was established in 1965 in Barcelona, Catalonia, as a specialist company serving the health-science and pharmaceutical information markets. Its publishing and information activities focused on pharmacology, drug discovery, biomedical research, and related scientific disciplines. Rather than operating as a general-interest publisher, the company developed subject-specific resources for researchers, pharmaceutical professionals, and other users of technical biomedical information. The company built an international operating footprint from its Spanish base. Reference material identifies offices or subsidiaries in Philadelphia in the United States, Buenos Aires in Argentina, and Tokyo in Japan, in addition to its Barcelona headquarters. This structure supported the distribution of its scientific products across multiple geographic markets and reflected the international character of pharmaceutical and biomedical research. Prous Science also pursued the use of computational methods to organize and interpret scientific data. Its research model combined data mining, statistical analysis, and chemoinformatics with laboratory techniques including combinatorial chemistry, molecular biology, and functional genomics. The company used the term “druginformatics” for this integrated approach to drug-related information and research. The concept represented an attempt to connect large-scale scientific data analysis with practical drug-discovery and biomedical investigation. In 2000, the Prous Institute for Biomedical Research was created as a biotechnology spin-off of Prous Science. Dr. Josep Prous Jr. founded the institute, which extended the organization's work beyond publishing into biomedical and drug-discovery research. Its methods included computational analysis as well as experimental laboratory approaches. The institute therefore served as a research-oriented complement to the company's information and publishing business. Prous Science launched the Prous Scientific Integrity data portal in 2001. The portal demonstrated the company's movement toward digital, structured, and searchable scientific information services. It formed part of a broader transition in technical publishing, in which specialized content was increasingly delivered through databases and online platforms rather than only through printed reference works. The company's corporate history changed in 2007, when Thomson Reuters acquired Prous Science. The acquisition placed Prous's specialist pharmacology and drug-discovery resources within a much larger global information-services company. In 2008, Prous pharmacology and drug-discovery content was made available through Thomson Reuters services. Public reference material does not provide sufficient information to determine the current legal status of the original Prous Science entity, the continuity of the brand as a standalone business, or a current executive structure. Its documented legacy is primarily as a specialist scientific publisher and biomedical information provider whose content and methods were incorporated into a larger information-services platform.
- 2008
Prous content integrated into Thomson Reuters services
[1]Prous pharmacology and drug-discovery content becomes available through Thomson Reuters services.
- 2007
Acquisition by Thomson Reuters
[1]Thomson Reuters acquires Prous Science.
- 2001
Prous Scientific Integrity portal launches
[1]Prous Science launches the Prous Scientific Integrity data portal.
- 2000
Prous Institute for Biomedical Research is founded
[1]The Prous Institute for Biomedical Research is founded by Josep Prous Jr. as a biotechnology spin-off of Prous Science.
- 1965
Prous Science is established
[1]Prous Science is established in Barcelona, Catalonia, as an international health-science publishing and information company.
Products and positioning
A specialist health-science information and publishing brand combining pharmaceutical and biomedical content with computational data analysis, chemoinformatics, and drug-discovery research.
Scientific data portal · 2001
Prous Scientific Integrity
Prous Scientific Integrity was a data portal launched in 2001. It represented the company's move toward organized digital scientific information and supported its broader positioning in specialized biomedical and pharmaceutical knowledge services.
Pharmaceutical information resources
Prous pharmacology and drug-discovery content
This body of specialized content covered pharmacology and drug discovery and formed a central part of Prous Science's publishing and information portfolio. Following the 2007 acquisition, the content was made available through Thomson Reuters services in 2008.
Health-science publishing
Prous scientific and biomedical publications
Prous Science produced specialized scientific publishing and reference material for health sciences, pharmacology, biomedical research, and pharmaceutical discovery. Specific publication titles and their current status are not established by the available reference material.
Brand decisions
2007
Sell the company to Thomson ReutersM&ABackground
Prous Science operated in specialized scientific publishing and information markets that were increasingly consolidating around large international information providers.
Action taken
Thomson Reuters acquired Prous Science.
Aftermath
Prous pharmacology and drug-discovery content was made available through Thomson Reuters services in 2008. The purchase price and detailed transaction terms are not provided in the available reference material.
2001
Launch the Prous Scientific Integrity data portalProduct launchBackground
Scientific publishing and pharmaceutical research were increasingly adopting digital databases and structured information systems.
Action taken
Prous Science launched the Prous Scientific Integrity data portal.
Aftermath
The launch strengthened Prous Science's role as a provider of digital scientific information, although detailed usage and commercial performance data are unavailable.
2000
Create a biotechnology research spin-offStrategyBackground
Prous Science sought to extend its scientific information and publishing activities into applied biomedical and drug-discovery research.
Action taken
The Prous Institute for Biomedical Research was established as a biotechnology spin-off, founded by Josep Prous Jr.
Aftermath
The institute became a research-oriented component of the wider Prous organization, using computational and laboratory methods.
Recent events
- 2008
Prous pharmacology and drug-discovery content becomes available through Thomson Reuters services[1]
Other
Following the acquisition, Prous scientific content was made available through Thomson Reuters services.
- 2007
Thomson Reuters acquires Prous Science[1]
M&A
Thomson Reuters acquired Prous Science, bringing the specialist publisher's pharmacology and drug-discovery information into the Thomson Reuters information-services portfolio.
- 2001
Prous Scientific Integrity data portal launches[1]
Product launch
Prous Science launched the Prous Scientific Integrity data portal as part of its effort to provide structured scientific and biomedical information.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/prous-science · Editorial policy · How profiles are compiled